Shire’s angioedema drug succeeds in late-stage study
Shire Plc said successful late-stage data on its long-acting drug for hereditary angioedema would form the basis of a U.S. marketing application for the treatment. U.S.-listed shares of company, which...
View ArticleAstraZeneca phase IIIb/IV EXSCEL of Bydureon meets primary endpoint
AstraZeneca has announced top─line results from the phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial. The trial compared the effect of once─weekly Bydureon (exenatide...
View ArticleSwiss biotech NLS Pharma’s ADHD drug succeeds in mid-stage study
Swiss biotech NLS Pharma AG said on Wednesday mid-stage trial data showed that its drug to treat attention deficit hyperactivity disorder (ADHD) greatly reduced symptoms in adults, paving the way for a...
View ArticleImmuno-oncology upset in bladder cancer
Roche and Genentech’s checkpoint inhibitor atezolizumab did not improve overall survival in a confirmatory phase III trial in patients with advanced bladder cancer. The FDA granted accelerated...
View ArticleNovartis touts new T-cell therapy data in race for FDA approval
Novartis on Wednesday touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite Pharma and Juno Therapeutics that also target aggressive...
View ArticleSanofi-Regeneron’s Praluent cuts cholesterol in Odyssey trials
France’s Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and...
View ArticleTwee fase-3 onderzoeken met sotagliflozine bij type 1 diabetespatiënten...
Sotagliflozin (SOTA) is een orale remmer van zowel SGLT-1 als SGLT-2. Al eerder is aangetoond dat het een effectief en goed getolereerd middel is om de bloedglucose in type 1 en type 2...
View ArticleType 1 Diabetes Reversal May be Possible with TB Vaccine
Faustman’s team is preparing for a 5-year, 150-person Phase 2 trial to investigate the potential for repeat BCG vaccination to improve type 1 diabetes in adults with existing disease. According to data...
View ArticleBoehringer Ingelheim presents phase III results demonstrating clinical...
Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and...
View ArticleBreakthrough study could revolutionise MS treatment
The results of a study from the University of California, San Francisco will be welcomed with a certain excitement from all quarters, given that it seems to show the repair of myelin damaged by...
View Article